AstraZeneca, Leo Pharma deal

AstraZeneca granted Leo exclusive, worldwide rights to tralokinumab ( CAT-354) for dermatological indications and exclusive, European rights to brodalumab ( KHK4827). For tralokinumab, AZ

Read the full 242 word article

How to gain access

Continue reading with a
two-week free trial.